The Claim
GLP-1 receptor agonist therapy for weight loss is associated with loss of both lean body mass (muscle) and fat mass.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People taking GLP-1 receptor agonists for weight loss lose muscle mass in addition to fat mass.
See the scientific wording
GLP-1 receptor agonist therapy for weight loss is associated with loss of lean body mass (muscle) in addition to fat mass.
GLP-1 receptor agonists make people feel full and eat less. This creates an energy deficit. The body then burns both fat and muscle for energy. Fat is lost mostly from the belly area, while muscle is lost more from the legs and non-dominant arm because those muscles are used less and break down faster during weight loss.
What the research says
3 studiesStudy: Effects of once-weekly semaglutide on regional body composition in overweight or obese adults
This study found that people taking the weight loss drug semaglutide lost both fat and muscle, with about 30% of the weight loss coming from muscle, confirming that muscle loss happens along with fat loss.
The study looked at many previous studies and found that people taking GLP-1 drugs like Ozempic lose about 1.5 kilograms of muscle on average, which confirms that muscle loss is a real side effect.
The study found that people taking semaglutide lost about the same amount of muscle as those not taking it, and lost more fat, so the idea that these drugs cause extra muscle loss is not supported.
Related videos
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 3 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.